Website
News25/Ratings5
Latest news
25 items- SECChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Niagen Bioscience, Inc. (0001386570) (Filer)
- PRChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol "NAGE" effective at stock market open on Wednesday, March 19, 2025. As part of this transition, the Company will deploy a follow-up announcement with additional updates regarding the name change, rebrand, and future initiatives. No action is required by existing shareholders with respect to the ticker symbol change. The Company's common stock will continue to be listed on Nasdaq and the CUSIP will remain unchanged. For additional
- PRChromaDex to Present at the 37th Annual Roth ConferenceChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference. ChromaDex CEO, Rob Fried, will participate on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT (3:00 PM ET). Panels will be livestreamed and available at https://wsw.com/webcast/roth50. Additionally, ChromaDex's CEO, Rob Fried, and CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutional investors throughout the day. This year's event will consist of one-on-one and small group meetings, analyst-selected fireside
- INSIDERSVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)4 - ChromaDex Corp. (0001386570) (Issuer)
- SECChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ChromaDex Corp. (0001386570) (Filer)
- PRChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 ResultsFull year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior year, gross margin of 62.5%, and net income of $7.2 million. ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter. Posted strong gross margin of 62.5%, up 150 basis points from 61.0%
- SECSEC Form 10-K filed by ChromaDex Corporation10-K - ChromaDex Corp. (0001386570) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Fried Robert N4 - ChromaDex Corp. (0001386570) (Issuer)
- SECChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ChromaDex Corp. (0001386570) (Filer)
- PRChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2024 financial results, which ended December 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, March 4, 2025. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the fourth quarter and fiscal year 2024 results and provide a general business update on Tuesday, March 4, 2
- INSIDERSEC Form 4 filed by SVP, General Counsel Lopez Carlos Luis4 - ChromaDex Corp. (0001386570) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Pamir Ozan4 - ChromaDex Corp. (0001386570) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Fried Robert N4 - ChromaDex Corp. (0001386570) (Issuer)
- PRChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The company presentation will take place at 12:00 p.m. ET on Monday, January 13, 2025. The webcast can be accessed directly at https://lythampartners.com/health2025/cdxc or by visiting the conference home page at https://lythampartners.com/health2025/. A replay of the presentation will also be available through the same links. 1x1 investor meetings will be available
- SECChromaDex Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant8-K - ChromaDex Corp. (0001386570) (Filer)
- INSIDERDirector Jaksch Frank L Jr exercised 50,001 shares at a strike of $3.66 and sold $229,956 worth of shares (37,161 units at $6.19), increasing direct ownership by 6% to 244,179 units (SEC Form 4)4 - ChromaDex Corp. (0001386570) (Issuer)
- SECChromaDex Corporation filed SEC Form 8-K: Other Events8-K - ChromaDex Corp. (0001386570) (Filer)
- PRChromaDex Named to the Inc. 2024 Best in Business List in the Health Products CategoryChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made an impact on their industries and society at large. This recognition underscores ChromaDex's industry-leading NAD+ research and its expanding portfolio of healthy aging products featuring Niagen® (patented nicotinamide riboside or NR), the most efficient and high-quality NAD+ precursor. Such products include the direct-to-consumer dietary supplement, Tru Niagen®, and the newly unveiled pharmaceutical-grade Niagen IV. "Our mission is t
- INSIDERChief Financial Officer Pamir Ozan bought $21,397 worth of shares (2,907 units at $7.36) (SEC Form 4)4 - ChromaDex Corp. (0001386570) (Issuer)
- SECSEC Form 424B3 filed by ChromaDex Corporation424B3 - ChromaDex Corp. (0001386570) (Filer)
- SECChromaDex Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - ChromaDex Corp. (0001386570) (Filer)
- PRChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity SupplementThe gold standard in NAD+ supplementation, Niagen® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology's new supplement ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announces that its flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is the hero ingredient in Longevity.Technology's inaugural supplement called Longevity.Technology® LONGEVITY. Designed to support a healthier, longer life, the supplement includes Niagen, the gold standard ingredient for enhancing NAD+ levels and optimizing cellular health. Longevity.Technology,
- INSIDERNew insider Lopez Carlos Luis claimed ownership of 1,978 shares (SEC Form 3)3 - ChromaDex Corp. (0001386570) (Issuer)
- PRChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics NationwideNational rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States. This represents a major milestone, making Niagen IV—a significant advancement in intravenous NAD+ therapy—more widely accessible to wellness enthusiasts looking to enhance cellular health and extend their healthspan. Available in oral and IV
- PRChromaDex Corporation Reports Third Quarter 2024 Financial ResultsTotal net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. Delivered strong gross margin of 63.5%, up 210 basis poi